Marinus Pharmaceuticals Statistics
Total Valuation
MRNS has a market cap or net worth of $75.68 million. The enterprise value is $37.35 million.
| Market Cap | 75.68M |
| Enterprise Value | 37.35M |
Important Dates
The next estimated earnings date is Thursday, May 9, 2024, before market open.
| Earnings Date | May 9, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
MRNS has 54.64 million shares outstanding. The number of shares has increased by 37.56% in one year.
| Shares Outstanding | 54.64M |
| Shares Change (YoY) | +37.56% |
| Shares Change (QoQ) | +5.19% |
| Owned by Insiders (%) | 0.97% |
| Owned by Institutions (%) | 106.80% |
| Float | 38.28M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.54 |
| Forward PS | 1.89 |
| PB Ratio | 4.69 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.21 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.07, with a Debt / Equity ratio of 6.50.
| Current Ratio | 4.07 |
| Quick Ratio | 3.79 |
| Debt / Equity | 6.50 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -7.46 |
Financial Efficiency
Return on equity (ROE) is -264.60% and return on invested capital (ROIC) is -104.59%.
| Return on Equity (ROE) | -264.60% |
| Return on Assets (ROA) | -70.70% |
| Return on Capital (ROIC) | -104.59% |
| Revenue Per Employee | $187,812 |
| Profits Per Employee | -$857,000 |
| Employee Count | 165 |
| Asset Turnover | 0.16 |
| Inventory Turnover | 1.55 |
Taxes
| Income Tax | -1.54M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -83.09% in the last 52 weeks. The beta is 0.89, so MRNS's price volatility has been lower than the market average.
| Beta (1Y) | 0.89 |
| 52-Week Price Change | -83.09% |
| 50-Day Moving Average | 7.71 |
| 200-Day Moving Average | 8.11 |
| Relative Strength Index (RSI) | 14.47 |
| Average Volume (30 Days) | 1,741,572 |
Short Selling Information
The latest short interest is 3.47 million, so 6.36% of the outstanding shares have been sold short.
| Short Interest | 3.47M |
| Short Previous Month | 3.57M |
| Short % of Shares Out | 6.36% |
| Short % of Float | 9.08% |
| Short Ratio (days to cover) | 6.33 |
Income Statement
In the last 12 months, MRNS had revenue of $30.99 million and -$141.41 million in losses. Loss per share was -$2.63.
| Revenue | 30.99M |
| Gross Profit | 29.06M |
| Operating Income | -131.49M |
| Pretax Income | -142.94M |
| Net Income | -141.41M |
| EBITDA | -125.31M |
| EBIT | -126.05M |
| Loss Per Share | -$2.63 |
Balance Sheet
The company has $150.29 million in cash and $108.95 million in debt, giving a net cash position of $41.34 million or $0.76 per share.
| Cash & Cash Equivalents | 150.29M |
| Total Debt | 108.95M |
| Net Cash | 41.34M |
| Net Cash Per Share | $0.76 |
| Equity / Book Value | 16.77M |
| Book Value Per Share | 0.31 |
| Working Capital | 124.62M |
Cash Flow
In the last 12 months, operating cash flow was -$118.00 million and capital expenditures -$110,000, giving a free cash flow of -$118.11 million.
| Operating Cash Flow | -118.00M |
| Capital Expenditures | -110,000 |
| Free Cash Flow | -118.11M |
| FCF Per Share | -$2.20 |
Margins
Gross margin is 93.76%, with operating and profit margins of -424.30% and -456.31%.
| Gross Margin | 93.76% |
| Operating Margin | -424.30% |
| Pretax Margin | -461.27% |
| Profit Margin | -456.31% |
| EBITDA Margin | -404.37% |
| EBIT Margin | -406.75% |
| FCF Margin | -381.14% |
Dividends & Yields
MRNS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -37.56% |
| Shareholder Yield | -37.56% |
| Earnings Yield | -179.71% |
| FCF Yield | -150.11% |
Analyst Forecast
The average price target for MRNS is $13.75, which is 892.78% higher than the current price. The consensus rating is "Buy".
| Price Target | $13.75 |
| Price Target Difference | 892.78% |
| Analyst Consensus | Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (5Y) | 71.65% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on September 23, 2020. It was a reverse split with a ratio of 1:4.
| Last Split Date | Sep 23, 2020 |
| Split Type | Reverse |
| Split Ratio | 1:4 |
Scores
MRNS has an Altman Z-Score of -5.76 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -5.76 |
| Piotroski F-Score | 3 |